Induced Pluripotent Stem Cell (iPSC) reprogramming and organoid systems are transformative pillars of global regenerative medicine, addressing critical unmet healthcare needs including organ donor shortages, limited understanding of disease mechanisms, and low success rates in novel drug development. With breakthroughs across cardiovascular, neurological, oncological, and other fields—from clinical trials of iPSC-based therapies to organoids serving as the gold standard for personalized drug screening—these technologies are driving the global paradigm shift toward precision and regenerative medicine, aligned with worldwide biomedical innovation priorities.

Mapping Lab's core platform provides end-to-end support for iPSC and organoid research. It synchronously captures electrical and calcium dynamics across scales—from single cells to organoids—establishing a global standard for maturity assessment and batch effect elimination. The platform generates regulatory-compliant (CiPA/FDA) electrophysiological data, supports patient-specific disease modeling, and offers a modular workflow to accelerate drug development, animal-free testing, and clinical translation in regenerative medicine.